PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Cut to $28.00 by Analysts at Piper Sandler

PROCEPT BioRobotics (NASDAQ:PRCT) had its price target trimmed by Piper Sandler from $50.00 to $28.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

PRCT has been the topic of a number of other reports. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Bank of America lowered shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $38.00 to $20.00 in a research report on Thursday. Finally, UBS Group assumed coverage on PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

PROCEPT BioRobotics Price Performance

NASDAQ PRCT opened at $23.63 on Thursday. PROCEPT BioRobotics has a 12 month low of $19.35 and a 12 month high of $68.70. The firm has a market capitalization of $1.32 billion, a PE ratio of -13.82 and a beta of 0.99. The company’s 50 day simple moving average is $30.18 and its 200 day simple moving average is $33.64. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. During the same period in the previous year, the business posted ($0.35) earnings per share. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, equities research analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRCT. Caitong International Asset Management Co. Ltd raised its stake in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares during the period. JTC Employer Solutions Trustee Ltd purchased a new position in shares of PROCEPT BioRobotics during the third quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics during the fourth quarter valued at $40,000. Vega Investment Solutions lifted its stake in PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares in the last quarter. Finally, US Bancorp DE lifted its stake in PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.